Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Comparison of infections in patients with chronic lymphocytic leukemia (CLL) treated with BTKi versus venetoclax obinutuzumab in first line therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

ZBZubair Hassan Bodla

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows increased bacterial pneumonia and urinary tract infections in CLL with BTKi, indicating safety concerns.

Key Points

  • Increased rates of bacterial pneumonia in CLL patients treated with BTKi compared to venetoclax.
  • A total of 10.4% of patients on BTKi developed urinary tract infections versus 5.5% on venetoclax.
  • Analysis of infection rates was conducted using data from over 16,000 CLL patients across healthcare organizations.
  • The findings suggest significant safety implications for treatment with BTKi in chronic lymphocytic leukemia.

Cite This Study

Zubair Hassan Bodla (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d86chttps://doi.org/10.1182/blood-2025-3884
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  2. 2Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials2025
  3. 3Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors – systematic review and meta-analysis of randomized controlled trials2025
  4. 4Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis2025
  5. 5Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis2025